Sep 2026· European journal of medicinal chemistry· Vol 320, pp. 119319 - 119319· 0 citations· 52 references
Medicine
TL;DR
Treatment of AD patient-derived hiPSC glia cells including microglia and astrocytes and neuropathic pain mice with 22 led to suppression of NLRP3 expression and decreased pain and pain-like behavior, supporting the translational promise of this compound and analogs from this chemotype.
Abstract
In our continuing campaign to discover novel inhibitors of the nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) protein 3 (NLRP3), an emerging drug target that tightly regulates the innate immune responses, a 1H-1,2,3-triazole-4-carboxamide scaffold was designed and optimized. Iterative optimization led to the identification of a lead inhibitor, 22, with an IC50 of 70 nM to suppress the release of interleukin (IL)-1β upon NLRP3 activation. Further in vivo studies supported its selective suppression of the NLRP3 inflammasome. Pharmacokinetic studies of 22 and PET imaging studies employing a F-18 tracer of 22 demonstrated 22 as a brain penetrant with reversible binding kinetics within the CNS. Importantly, treatment of AD patient-derived hiPSC glia cells including microglia and astrocytes and neuropathic pain mice with 22 led to suppression of NLRP3 expression and decreased pain and pain-like behavior, supporting the translational promise of this compound and analogs from this chemotype.
In human induced pluripotent stem cell-derived microglia, compound 4 reduced SHP1/2 phosphorylation, attenuated NF-κB activation and IL-1β secretion, and restored Aβ uptake without compromising cell viability, and the compound exhibited oral bioavailability and brain penetration.
S. Abdel-Rahman, M. Gabr· Bioorganic chemistry (Print)· 1 citation
Optimization of ligands targeting Cys463 of NLRP3 within a previously uncharacterized allosteric pocket led to a unique and potent inhibitor series with attractive physicochemical and pharmacokinetic properties for the potential treatment of diseases involving aberrant innate immune activation in both central and perip...
Donald C. Rogness, E. Sievert, Vincent F Vartabedian et al.· British Journal of Pharmacol...· 1 citation
The NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome is an established driver of inflammation in diseases such as diabetes, Alzheimer's disease, and gout. Previously, we screened 875 FDA-approved drugs for NLRP3 inhibitors and identified ponatinib as one of the five candidates that reduced NLRP3...
Abigail H. Evered, Daniel C. Shippy, Jaidynne N. Lash et al.· Immunobiology· 0 citations
Accumulating evidence indicates that glial cells play a critical role in the initiation, maintenance, and resolution of neuropathic pain. However, there is lack of glia-specific molecular targets for pain management. We recently identified the G protein-coupled receptor GPR37-like 1 (GPR37L1) as a glia-selective recept...
Sharat Chandra, Jing Xu, S. Bang et al.· Pain· 0 citations
It is demonstrated that compound 4b exerts NLRP3 inhibitory activity in CNS-resident innate immune cells and modulates neuroinflammation and functional recovery after TBI, supporting its further development as a mechanistically validated NLRP3 inhibitor with translational relevance.
Céline Decouty-Pérez, María Álvarez-Rubal, Icíar Polo-Fernández et al.· ACS Pharmacology & Trans...· 0 citations
Innate immune signaling through inflammasome activation has been implicated in the pathogenesis of multiple sclerosis (MS). We previously demonstrated that nucleoside reverse transcriptase inhibitors (NRTIs), drugs approved to treat HIV and hepatitis B virus infections, and kamuvudines, safer NRTI derivatives, both inh...
P. Yerramothu, Kameshwari Ambati, Joseph Magagnoli et al.· Science Translational Medici...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.